Skip to content

Cardiopulmonary Register for Intensive Care Medicine Aachen

Cardiopulmonary Register for Intensive Care Medicine Aachen - AIX-INTENS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00039174
Enrollment
500
Registered
2026-04-20
Start date
2026-05-04
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic shock and acute respiratory distress syndrome (lung failure, ARDS)

Interventions

Group 1: Observational study including all patients hospitalised in the cardiology/pulmonology intensive care unit (IM 18/IM19) of the University Hospital RWTH Aachen due to cardiogenic shock or ARDS.

Sponsors

Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients admitted to the intensive care unit with the primary clinical picture of cardiogenic shock or ARDS - Defining criteria for cardiogenic shock: o RR 2 mmol/l or other signs of end-organ hypoperfusion (AKI, hepatopathy) - Definitional criteria for ARDS: o Presence of bilateral, non-cardiac infiltrates o Respiratory failure requiring intubation with Horowitz index =300 mmHg at PEEP =5 cmH20 or respiratory failure not requiring intubation with Horowitz index =300 mmHg and need for non-invasive ventilation with high-flow oxygen therapy (= 30 L/min) or NIV-CPAP (PEEP = 5 cmH20)

Exclusion criteria

Exclusion criteria: Pregnancy and breastfeeding - Cardiogenic shock/ARDS as a progressive clinical picture in patients already being treated in intensive care for a primarily different clinical picture - Cardiogenic shock/ARDS as a complication of surgery - Following heart and/or lung transplantation - Metastatic cancer

Design outcomes

Primary

MeasureTime frame
Mortality during hospitalisation - Length of stay in intensive care - Need for mechanical circulatory support/extracorporeal membrane oxygenation (ECMO) - Duration of treatment for ECMO patients - Development of dialysis-dependent renal failure - Development of chronic heart failure (LV dysfunction, diastolic dysfunction, RV dysfunction) - Development of hypoxic brain damage in IHCA/OHCA patients - Development of major bleeding (including ICB) under MCS/ECMO - 6-month survival and outcome in terms of organ function and quality of life

Countries

Germany

Contacts

Public ContactKirsten Thiele

Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin

kithiele@ukaachen.de+49 241 80 35137

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026